Jubilant Ingrevia announced its financial results for the second quarter of FY27, reporting a 24% year-on-year increase in revenue, reaching ₹1,394 crore. EBITDA also saw a substantial 51% YoY growth, amounting to ₹221 crore. The company highlighted strong performance across its segments, driven by improved pricing and volume growth, and also announced a 40% stake acquisition in ZettaOne Technologies.
Jubilant Ingrevia Reports Strong Q2 FY27 Performance
Jubilant Ingrevia Limited has declared its financial results for the quarter and half-year ended September 30, 2026, showcasing significant growth across key financial metrics. The company’s revenue from operations reached an all-time high of ₹1,394 crore in Q2 FY27, marking a substantial 24% increase compared to the same period in the previous year. This growth was attributed to stronger realizations and stable volumes, reflecting disciplined execution across its business segments.
EBITDA and Profitability Surge
The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) demonstrated robust growth, increasing by 51% year-on-year to ₹221 crore in Q2 FY27. The EBITDA margin stood at 16%. Profit After Tax (PAT) after exceptional items also saw a healthy increase of 61% YoY, reaching ₹111 crore. The reported Basic and Diluted Earnings Per Share (EPS) for the quarter was ₹7.1, a 61% increase from the previous year.
Half-Yearly Performance Highlights
For the first half of FY27 (H1 FY27), Jubilant Ingrevia reported a total revenue of ₹2,695 crore, up 25% YoY. The H1 FY27 EBITDA grew by 44% YoY to ₹431 crore. PAT after exceptional items for H1 FY27 was ₹217 crore, a 50% increase YoY. The half-yearly EPS stood at ₹13.8, reflecting a 50% jump from H1 FY26.
Strategic Acquisition in Electronics Sector
In a significant strategic move, Jubilant Ingrevia announced the acquisition of a 40% stake in ZettaOne Technologies Limited for ₹189.2 crore. This acquisition marks the company’s entry into the Electronic Design and Manufacturing Services (EDMS) space, aiming to offer an integrated value proposition to customers in the electronics and semiconductor sectors. ZettaOne is projected to grow by 60-70% in the current year.
Segmental Performance Overview
Specialty Chemicals
The Specialty Chemicals segment reported revenue of ₹560 crore in Q2 FY27, an increase of 16% YoY. EBITDA for the segment was ₹140 crore, with an EBITDA margin of 25%. Growth was driven by Fine Chemicals and CDMO, with stable volumes in Pyridine & Picolines despite pricing softness.
Nutrition & Health Solutions
This segment achieved revenue of ₹270 crore, a robust 50% YoY growth. EBITDA increased by 87% YoY to ₹39 crore. The growth was propelled by strong volume increases in Vitamin B3 and a favorable mix of value-added products in human and animal nutrition.
Chemical Intermediates
Chemical Intermediates segment revenue grew by 24% YoY to ₹563 crore. EBITDA saw a significant jump of 226% YoY to ₹64 crore. The segment benefited from improved realizations, especially in Acetic Anhydride and Ethyl Acetate, with a competitor closure in Europe expected to boost pricing and demand.
Source: BSE
